MariMed Reports Record 2025 Revenue as Wholesale Strength Offsets Pricing Pressure

MariMed, a brand‑driven MSO with a focused footprint across the Northeast and Midwest, closed out 2025 with the kind of steady, disciplined performance that has become its hallmark, posting record revenue, positive adjusted EBITDA for the sixth straight year, and meaningful gains in wholesale distribution despite persistent price compression across key markets. The results released on Wednesday reflect a company that has leaned into its strengths and stayed consistent while much of the industry has been forced to retrench. 

“I’m proud of our performance in the fourth quarter, particularly in such a challenging environment,” MariMed president and CEO Jon Levine writes in a statement to IgniteIt. “Revenue grew sequentially and year-over-year for the quarter, driven by the strength of our wholesale channel, and also growth we achieved at retail at the end of the year.”

“On the wholesale front, we ended the year with 85 percent penetration and the #1-selling edible across our core markets of Massachusetts, Maryland, Illinois, and Delaware,” Levine continues. “At retail, we grew revenue 4% sequentially and also increased our transactions, indicating that a number of initiatives we implemented worked. Looking ahead to 2026, our focus remains on expanding our brand distribution, capturing more shelf space in existing markets and entering new ones through licensing and M&A.”

Fourth-Quarter and Full-Year Performance

MariMed reported $41.7 million in fourth-quarter revenue, up from $38.9 million a year earlier. Full-year revenue reached $159.8 million, a slight increase from 2024. While modest, the growth is notable in a year when many operators saw flat or declining sales amid wholesale price drops.

Margins tightened under those same pressures. GAAP gross margin fell to 36% for the year, and adjusted EBITDA declined to $16.9 million from $19.3 million in 2024. The company posted a GAAP net loss of $14.5 million. Even so, MariMed extended its streak of positive adjusted EBITDA to six years, a level of consistency that has become increasingly rare among mid-sized MSOs.

Wholesale Strength and Brand Momentum

Wholesale remained the company’s strongest driver, growing 11% year-over-year. MariMed now distributes to 85% of dispensaries in its core markets, giving it one of the deepest wholesale footprints among independent operators.

Betty’s Eddies continued to lead the portfolio, ranking as the top-selling edible across Massachusetts, Maryland, Delaware, and Illinois. Vibations, the company’s drink mix, finished as the fourth-best-selling cannabis beverage across those same states. Strong brand performance has helped MariMed maintain stability in markets where pricing pressure has challenged operators without established consumer loyalty.

Strategic Moves and Balance Sheet Positioning

MariMed spent the fourth quarter sharpening its focus. It exited Missouri after a strategic review and signed a licensing agreement in New York that will allow it to distribute its brands once a new kitchen is completed and regulatory approvals are secured.

The company also extended the maturity of its Series B obligation by 4.6 years, strengthening liquidity at a time when many operators face near-term refinancing needs. With no material debt maturities approaching, MariMed enters 2026 in a comparatively strong financial position.

Growth Drivers for 2026

MariMed expects several catalysts to support growth this year. Delaware’s adult-use market, which launched last August, will contribute a full year of revenue. MariMed also began brand distribution in Maine late in 2025 and plans to open a new dispensary in the Ohio market during 2026.

“Looking ahead to 2026, we have a number of drivers to fuel our growth,” MariMed CFO Mario Pinho said in a press release. “These include: a full year of financial contribution following the launch of adult-use cannabis sales in Delaware last August and the launch of our brand distribution in Maine through a new licensing partner during the fourth quarter of 2025; and revenue generated by the new Columbus, Ohio, dispensary we intend to open during the year.”

How MariMed Is Positioned Going Forward

MariMed’s 2025 results reinforce its position as a steady operator in a volatile sector. Strong brands, disciplined spending, and a focused footprint have allowed it to maintain momentum while many peers continue to recalibrate. With pricing pressure likely to persist and capital still tight, operators that can grow without leaning on debt or aggressive expansion remain better positioned for the next phase of the market.